Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.
If you're serious about closing the risk strategy-culture gap, a good starting point can be found in the following approaches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback